Find trials
Search tips

Relationship Between Nectin-4-Positive Exosomes in Blood and Urine and the Response to Enfortumab Vedotin Therapy

Overview

About this study

The purpose of this study is to assess the relationship between Nectin-4-positive exosomes in blood and urine and the response to Enfortumab vedotin therapy.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Confirmed diagnosis of urothelial cancer.
  • Scheduled to initiate antibodydrug conjugate (ADC) therapy.
  • Willing and able to provide informed consent.

Exclusion Criteria:

  • Inability or unwillingness to provide informed consent.
  • Any medical condition or treatment that, in the investigator's judgment, would interfere with the study's objectives.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/20/2024. Questions regarding updates should be directed to the study team contact.
 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jacob Orme, M.D., Ph.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20563503

Mayo Clinic Footer